Who are EXDENSUR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Benralizumab Prefilled Syringe, anti IL5 receptor antibodies, Fasenra®, Mepolizumab Injection [Nucala], Asthma therapies, Placebo matching mepolizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/depemokimab-ulaa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

EXDENSUR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EXDENSUR (DEPEMOKIMAB-ULAA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

marketed IL-5 Other Live · refreshed every 30 min

Target snapshot

EXDENSUR (DEPEMOKIMAB-ULAA) — GLAXOSMITHKLINE LLC. Depemokimab-ulaa binds to IL-5, blocking its interaction with the IL-5 receptor and reducing eosinophil activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EXDENSUR TARGET	DEPEMOKIMAB-ULAA	GLAXOSMITHKLINE LLC	marketed		IL-5
Benralizumab Prefilled Syringe	Benralizumab Prefilled Syringe	Nantes University Hospital	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor alpha (IL-5Rα)
anti IL5 receptor antibodies	anti IL5 receptor antibodies	Scarlata, Simone, M.D.	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5 receptor (IL-5R)
Fasenra®	Fasenra®	AstraZeneca	marketed	IL-5 receptor antagonist monoclonal antibody	IL-5Rα (interleukin-5 receptor alpha)
Mepolizumab Injection [Nucala]	Mepolizumab Injection [Nucala]	KU Leuven	marketed	IL-5 antagonist monoclonal antibody	IL-5 (Interleukin-5)
Asthma therapies	Asthma therapies	Genentech, Inc.	marketed	Monoclonal antibodies (multiple agents with different targets)	IgE, IL-5, IL-4 receptor alpha (varies by specific agent)
Placebo matching mepolizumab	Placebo matching mepolizumab	GlaxoSmithKline	phase 3	IL-5 inhibitor	IL-5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EXDENSUR — Competitive Intelligence Brief. https://druglandscape.com/ci/depemokimab-ulaa. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing